Hanwha Of S. Korea Inks Deal With Merck For Enbrel Biosimilar
This article was originally published in PharmAsia News
Executive Summary
South Korea's Hanwha Chemical and Merck & Co.'s Merck Sharp and Dohme Research have reached a licensing agreement to develop and commercialize Hanwha's biosimilar HD203, a version of Amgen Inc.'s blockbuster rheumatoid arthritis drug Enbrel (etanercept)